EP1664008A1 - Process for the preparation of amorphous form of repaglinide - Google Patents

Process for the preparation of amorphous form of repaglinide

Info

Publication number
EP1664008A1
EP1664008A1 EP04769193A EP04769193A EP1664008A1 EP 1664008 A1 EP1664008 A1 EP 1664008A1 EP 04769193 A EP04769193 A EP 04769193A EP 04769193 A EP04769193 A EP 04769193A EP 1664008 A1 EP1664008 A1 EP 1664008A1
Authority
EP
European Patent Office
Prior art keywords
repaglinide
amoφhous
amoφhous form
process according
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769193A
Other languages
German (de)
French (fr)
Inventor
Yatendra Kumar
Purna Chandra Ray
Jayachandra Suresh Babu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1664008A1 publication Critical patent/EP1664008A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

  • repaglinide is S(+)-2-ethoxy-4-[N-(l-(2-piperidino-phenyl)-3-methyl- l-butyl)-aminocarbonylmethyl]benzoic acid, which belongs to a new class of hypoglycemic benzoic acid derivatives.
  • 5,216,167 discloses enantiomers, diastereomers, non-toxic salts and non-toxic acid addition salts of repaglinide.
  • repaglinide which has a melting point of 102 to 104 °C, is prepared by recrystallizing from petroleum ether/toluene.
  • U.S. Patent No. 6,143,769 discloses a process for preparing repaglmide, which has a melting point of 126 to 131 °C, by recrystallizing from ethanol/water.
  • repaglinide that is available in other physical forms, such as, for example, amorphous form.
  • the present invention also encompasses repaglinide in an amorphous form.
  • the amorphous form of repaglinide is characterized by a differential scanning calorimetry curve having a single melting endotherm with a peak temperature of about 52.98 °C and an extrapolated onset temperature of about 47.23 °C.
  • the present invention further encompasses a method of treating a disease related to hypoglycemic activity comprising administering a therapeutically effective amount of an amo ⁇ hous form of repaglinide to a patient in need thereof.
  • the present invention also encompasses a method of treating diabetes mellitus comprising administering a therapeutically effective amount of an amo ⁇ hous form of repaglinide to a patient in need thereof.
  • the patient is a human.
  • the present invention encompasses a process for the preparation of an amo ⁇ hous form of repaglinide, which comprises recovering amo ⁇ hous repaglinide from a repaglinide solution by spray drying.
  • the repaglinide solution can be obtained directly from a reaction mixture, i another embodiment, the repaglinide solution can be obtained by dissolving crystalline repaglinide in a suitable solvent.
  • suitable solvents can be alcohols, ketones, ethers, chlorinated hydrocarbons, esters, nitriles, dipolar aprotic solvents, cyclic ethers, and mixtures thereof.
  • the suitable solvents can be methanol, ethanol, isopropanol, dichloromethane, dichloroethane, acetonitrile, tetrahydrofuran, dioxane, diethylether, diisopropylether, tertiary butylethylether, and mixtures thereof.
  • the air inlet temperature of the spray drier can be from about 40 °C to about 100 °C and outlet temperature of the spray drier can be from about 20°C to about 80 °C.
  • the present invention also encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of an amo ⁇ hous form of repaglinide and at least one pharmaceutical acceptable excipient, carrier, or diluent.
  • the amo ⁇ hous form of repaglinide is characterized by a differential scanning calorimetry curve having a single melting endotherm with a peak temperature of about 52.98 °C and an extrapolated onset temperature of about 47.23 °C.
  • Fig. 1 is an X-ray diffraction spectrum of an amo ⁇ hous form of repaglinide.
  • Fig.2 is an IR spectrum of an amo ⁇ hous form of repaglinide obtained by using potassium bromide pellets.
  • the present invention encompasses a new form of repaglinide, and in particular, an amo ⁇ hous form of repaglinide.
  • the present invention encompasses a process for preparing an amo ⁇ hous form of repaglinide is provided comprising spray drying of a solution of repaglinide.
  • the present invention encompasses a pharmaceutical composition comprising an amo ⁇ hous form of repaglinide, along with pharmaceutically acceptable excipients.
  • the amo ⁇ hous form of repaglinide that is utilized in the pharmaceutical compositions is formed by recovering amo ⁇ hous repaglinide from a repaglinide solution by spray drying.
  • the present invention encompasses a method for treating or preventing diabetes mellitus, which comprises administering an effective amount of amo ⁇ hous form of repaglinide, is provided.
  • the amo ⁇ hous form of repaglinide is characterized by its non-crystalline nature.
  • the amo ⁇ hous form of repaglimde can be characterized by X-ray powder diffraction spectrum, or IR spectrum, as shown in Figures 1, and 2.
  • the amo ⁇ hous form of repaglinide also can be characterized by a differential scanning calorimetry (DSC) curve, which exhibits a single melting endotherm with a peak temperature of about 52.98°C and an extrapolated onset temperature of about 47.23°C.
  • DSC differential scanning calorimetry
  • the present invention also is directed to a process for preparing an amo ⁇ hous form of repaglinide comprising recovering amo ⁇ hous repaglinide from a solution in a suitable solvent by spray drying.
  • the solution of repaglinide can be obtained by dissolving crystalline repaglinide in a suitable solvent, or alternatively, such a solution may be obtained directly, from a reaction in which repaglinide is formed.
  • Any known forms of crystalline repaglinide can be used as a starting material, such as forms disclosed in U.S. Patent Nos. 5,216,167 and 6,143,769.
  • a solution of repaglinide obtained in-situ during the preparation process can be used as such for spray drying.
  • Repaglinide can be obtained by known methods, such as methods disclosed in U.S. Patent Nos. 5,216,167 and 6,143,769, and WO 03/027072.
  • suitable solvents include any solvent or solvent mixture in which repaglinide is soluble, hi particular, suitable solvents include, for example, alcohols, such as methanol, ethanol and isopropanol; ketones, such as acetone and methyl isobutyl ketone; ethers, such as diethylether, diisopropylether and tertiary butylethylether; nitriles, such as acetonitrile; chlorinated hydrocarbons, such as methylene chloride and ethylenedichloride; dipolar aprotic solvents, such as dimethylsulfoxide and dimethylformamide; esters, such as ethylacetate and isopropylacetate; cyclic ethers, such as dioxane and tetrahydrofuran and mixtures
  • Spray drying can be accomplished by using a spray dryer, which operates on the principle of nozzle spraying in a parallel flow, i.e., the sprayed product and the drying gas flow in the same direction.
  • the drying gas can be air, one or more inert gases, or a mixture thereof.
  • the inert gases can be nitrogen, argon or carbon dioxide.
  • the air inlet temperature of the spray drier can be from about 40 °C to about 100 °C and the outlet temperature can be from about 20 °C to about 80 °C.
  • the amo ⁇ hous form of repaglinide exhibits hypoglycemic activity.
  • the present invention encompasses a method of treating or preventing a disease related to hypoglycemic activity comprising administering amo ⁇ hous form of repaglinide to a patient in need of such treatment.
  • the present invention encompasses a method of treating or preventing diabetes mellitus comprising administering amo ⁇ hous form of repaglinide to a patient in need of such treatment.
  • the patient is human.
  • the amo ⁇ hous form of repaglinide can be administered as part of a pharmaceutical composition.
  • the present invention encompasses a pharmaceutical composition that comprises an effective amount of an amo ⁇ hous form of repaglinide along with a pharmaceutically acceptable carrier, diluent or excipient, and optionally one or more other therapeutic ingredients.
  • a pharmaceutically acceptable carrier diluent or excipient
  • the amo ⁇ hous form of repaglinide can be conventionally formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms. Any suitable route of administration may be employed, such as, for example, peroral or parental.
  • the pharmaceutical carrier can be a conventional solid or liquid carrier.
  • solid carriers include, but are not limited to, lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, corn and or potato starch, amylose, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, magnesium stearate, secondary calcium phosphate, polyoxyethylenepolyoxypropylene polymer, microcrystalline cellulose, N-methylglucamine, L-lysine and stearic acid.
  • liquid carriers include, but are not limited to, salt solutions, syrup, alcohols, polyethylene glycols, polyhydroxy ethoxylated castor oil, peanut oil, olive oil and water.
  • the carrier or diluent may include any time delay material well known to the art, such as, for example, glyceryl monostearate, glyceryl distearate, hydroxymethylcellulose and polyvinylpyrrolidone alone or mixed with a wax.
  • a solid carrier for oral administration the preparation can be formed into a tablet, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge.
  • the preparation may be a syrup, emulsion, soft gelatin capsule or sterile injectable liquid, such as an aqueous or non- aqueous liquid suspension.
  • compositions of this invention can be made following the conventional techniques of the pharmaceutical industry involving mixing, granulating and compressing or variously mixing and dissolving the ingredients as appropriate to give the desired end product.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as diluents, binders, lubricants, preservatives, disintegrants, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers, coloring agents, flavoring agents and the like, which do not deleteriously react with the active compound.
  • auxiliary agents such as diluents, binders, lubricants, preservatives, disintegrants, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers, coloring agents, flavoring agents and the like, which do not deleteriously react with the active compound.
  • FT-LR Instrument Perkin Elmer, 16 PC SCAN: 16scans, 4.0 cm "1 Run in accordance to the USP 25, general test methods, page 1920, infrared abso ⁇ tion spectra were obtained by potassium bromide pellet method.
  • Example 2 Crystalline repaglinide (lOg) was dissolved in 150 mL of acetone at room temperature. The clear solution thus obtained was subjected to spray drying in a mini spray dryer (Buchi Model 190).
  • the spray drier was configured to utilize a nitrogen gas inlet at 700mm of Hg and flow rate was set at 10.0 mL/minute. The inlet temperature was maintained at 56 °C and accordingly, the outlet temperature was 35 °C.
  • Repaglinide was charged in the spray drier for 15 minutes and 7.0 g of white fluffy powder was collected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel amorphous form of repaglinide and a process for preparaing the amorphous form. The precent invention also relates to pharmaceutical compositions comprising the amorphous form and its use in the treatment of diabetes mellitus.

Description

PROCESS FOR THE PREPARATION OF AMORPHOUS FORM OF REPAGLINIDE Technical Field of the Invention The present invention is directed to a novel amorphous form of repaglimde, a process for preparing the amorphous form, pharmaceutical compositions comprising the amoφhous form and a method of treating diabetes mellitus. Background of the Invention Chemically, repaglinide is S(+)-2-ethoxy-4-[N-(l-(2-piperidino-phenyl)-3-methyl- l-butyl)-aminocarbonylmethyl]benzoic acid, which belongs to a new class of hypoglycemic benzoic acid derivatives. U.S. Patent No. 5,216,167 discloses enantiomers, diastereomers, non-toxic salts and non-toxic acid addition salts of repaglinide. According to this patent, repaglinide, which has a melting point of 102 to 104 °C, is prepared by recrystallizing from petroleum ether/toluene. U.S. Patent No. 6,143,769 discloses a process for preparing repaglmide, which has a melting point of 126 to 131 °C, by recrystallizing from ethanol/water. However, there is a need for repaglinide that is available in other physical forms, such as, for example, amorphous form. The present invention also encompasses repaglinide in an amorphous form. The amorphous form of repaglinide is characterized by a differential scanning calorimetry curve having a single melting endotherm with a peak temperature of about 52.98 °C and an extrapolated onset temperature of about 47.23 °C. The present invention further encompasses a method of treating a disease related to hypoglycemic activity comprising administering a therapeutically effective amount of an amoφhous form of repaglinide to a patient in need thereof. The present invention also encompasses a method of treating diabetes mellitus comprising administering a therapeutically effective amount of an amoφhous form of repaglinide to a patient in need thereof. Preferably, the patient is a human. Summary of the Invention The present invention encompasses a process for the preparation of an amoφhous form of repaglinide, which comprises recovering amoφhous repaglinide from a repaglinide solution by spray drying. In one embodiment, the repaglinide solution can be obtained directly from a reaction mixture, i another embodiment, the repaglinide solution can be obtained by dissolving crystalline repaglinide in a suitable solvent. Preferred suitable solvents can be alcohols, ketones, ethers, chlorinated hydrocarbons, esters, nitriles, dipolar aprotic solvents, cyclic ethers, and mixtures thereof. In particular, the suitable solvents can be methanol, ethanol, isopropanol, dichloromethane, dichloroethane, acetonitrile, tetrahydrofuran, dioxane, diethylether, diisopropylether, tertiary butylethylether, and mixtures thereof. In another embodiment, the air inlet temperature of the spray drier can be from about 40 °C to about 100 °C and outlet temperature of the spray drier can be from about 20°C to about 80 °C. The present invention also encompasses a pharmaceutical composition comprising a therapeutically effective amount of an amoφhous form of repaglinide and at least one pharmaceutical acceptable excipient, carrier, or diluent. The amoφhous form of repaglinide is characterized by a differential scanning calorimetry curve having a single melting endotherm with a peak temperature of about 52.98 °C and an extrapolated onset temperature of about 47.23 °C. List of Figures Fig. 1 is an X-ray diffraction spectrum of an amoφhous form of repaglinide. Fig.2 is an IR spectrum of an amoφhous form of repaglinide obtained by using potassium bromide pellets. Detailed Description of the Invention h one aspect, the present invention encompasses a new form of repaglinide, and in particular, an amoφhous form of repaglinide. In another aspect, the present invention encompasses a process for preparing an amoφhous form of repaglinide is provided comprising spray drying of a solution of repaglinide. In yet another aspect, the present invention encompasses a pharmaceutical composition comprising an amoφhous form of repaglinide, along with pharmaceutically acceptable excipients. In one embodiment, the amoφhous form of repaglinide that is utilized in the pharmaceutical compositions is formed by recovering amoφhous repaglinide from a repaglinide solution by spray drying. In yet another aspect, the present invention encompasses a method for treating or preventing diabetes mellitus, which comprises administering an effective amount of amoφhous form of repaglinide, is provided. The amoφhous form of repaglinide is characterized by its non-crystalline nature. Additionally, the amoφhous form of repaglimde can be characterized by X-ray powder diffraction spectrum, or IR spectrum, as shown in Figures 1, and 2. The amoφhous form of repaglinide also can be characterized by a differential scanning calorimetry (DSC) curve, which exhibits a single melting endotherm with a peak temperature of about 52.98°C and an extrapolated onset temperature of about 47.23°C. The present invention also is directed to a process for preparing an amoφhous form of repaglinide comprising recovering amoφhous repaglinide from a solution in a suitable solvent by spray drying. The solution of repaglinide can be obtained by dissolving crystalline repaglinide in a suitable solvent, or alternatively, such a solution may be obtained directly, from a reaction in which repaglinide is formed. Any known forms of crystalline repaglinide can be used as a starting material, such as forms disclosed in U.S. Patent Nos. 5,216,167 and 6,143,769. A solution of repaglinide obtained in-situ during the preparation process can be used as such for spray drying. Repaglinide can be obtained by known methods, such as methods disclosed in U.S. Patent Nos. 5,216,167 and 6,143,769, and WO 03/027072. Suitable solvents include any solvent or solvent mixture in which repaglinide is soluble, hi particular, suitable solvents include, for example, alcohols, such as methanol, ethanol and isopropanol; ketones, such as acetone and methyl isobutyl ketone; ethers, such as diethylether, diisopropylether and tertiary butylethylether; nitriles, such as acetonitrile; chlorinated hydrocarbons, such as methylene chloride and ethylenedichloride; dipolar aprotic solvents, such as dimethylsulfoxide and dimethylformamide; esters, such as ethylacetate and isopropylacetate; cyclic ethers, such as dioxane and tetrahydrofuran and mixtures thereof; or mixtures thereof. Spray drying can be accomplished by using a spray dryer, which operates on the principle of nozzle spraying in a parallel flow, i.e., the sprayed product and the drying gas flow in the same direction. The drying gas can be air, one or more inert gases, or a mixture thereof. In particular, the inert gases can be nitrogen, argon or carbon dioxide. The air inlet temperature of the spray drier can be from about 40 °C to about 100 °C and the outlet temperature can be from about 20 °C to about 80 °C. The amoφhous form of repaglinide exhibits hypoglycemic activity. Accordingly, the present invention encompasses a method of treating or preventing a disease related to hypoglycemic activity comprising administering amoφhous form of repaglinide to a patient in need of such treatment. In another embodiment, the present invention encompasses a method of treating or preventing diabetes mellitus comprising administering amoφhous form of repaglinide to a patient in need of such treatment. Preferably, the patient is human. The amoφhous form of repaglinide can be administered as part of a pharmaceutical composition. Accordingly, in a further aspect, the present invention encompasses a pharmaceutical composition that comprises an effective amount of an amoφhous form of repaglinide along with a pharmaceutically acceptable carrier, diluent or excipient, and optionally one or more other therapeutic ingredients. The amoφhous form of repaglinide can be conventionally formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms. Any suitable route of administration may be employed, such as, for example, peroral or parental. The pharmaceutical carrier can be a conventional solid or liquid carrier. Examples of solid carriers include, but are not limited to, lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, corn and or potato starch, amylose, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, magnesium stearate, secondary calcium phosphate, polyoxyethylenepolyoxypropylene polymer, microcrystalline cellulose, N-methylglucamine, L-lysine and stearic acid. Examples of liquid carriers include, but are not limited to, salt solutions, syrup, alcohols, polyethylene glycols, polyhydroxy ethoxylated castor oil, peanut oil, olive oil and water. Similarly, the carrier or diluent may include any time delay material well known to the art, such as, for example, glyceryl monostearate, glyceryl distearate, hydroxymethylcellulose and polyvinylpyrrolidone alone or mixed with a wax. When a solid carrier for oral administration is used, the preparation can be formed into a tablet, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge. When a liquid carrier is used, the preparation may be a syrup, emulsion, soft gelatin capsule or sterile injectable liquid, such as an aqueous or non- aqueous liquid suspension. The pharmaceutical compositions of this invention can be made following the conventional techniques of the pharmaceutical industry involving mixing, granulating and compressing or variously mixing and dissolving the ingredients as appropriate to give the desired end product. The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as diluents, binders, lubricants, preservatives, disintegrants, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers, coloring agents, flavoring agents and the like, which do not deleteriously react with the active compound. Examples In the following section, embodiments are described by way of example to illustrate the process of invention. However, these examples are not intended, in any way, to limit the scope of the present invention. Several yariants of these examples would be evident to persons ordinarily skilled in the art.
METHODS The following instruments and configurations thereof were utilized in the examples described below.
1. Powder XRD X-Ray Difractometer, Rigaku Coφoration, RU-H3R Goniometer CN2155A3 X-Ray tube with Cu target anode Divergence slits 1 0, Receiving slit 0.15mm, Scatter slit 1 0 Power: 40 KV, 100 mA Scanning speed: 2 deg/min step: 0.02 deg Wave length: 1.5406 A
2. FT-LR Instrument: Perkin Elmer, 16 PC SCAN: 16scans, 4.0 cm"1 Run in accordance to the USP 25, general test methods, page 1920, infrared absoφtion spectra were obtained by potassium bromide pellet method.
3. DSC DSC821 e, Mettler Toledo Sample weight: 3-5 mg Temperature range: 30-180° C Heating rate: 5° C/min Nitrogen 80.0 mL/min Number of holes in the crucible: 1 Example 1 Crystalline repaglinide (lOg) was dissolved in 50 mL of methanol at 28-30 °C. The clear solution thus obtained was subjected to spray drying in a mini spray dryer (Buchi Model 190). The spray drier was configured to utilize a nitrogen gas inlet at 600 mm of Hg and a' flow rate was set at 10.0 mL/minute. The inlet temperature was maintained at 84 °C and accordingly, the outlet temperature was 76 °C. Repaglinide was charged in the spray drier for 5 minutes and 6.5 g of white fluffy powder was collected.
Moisture content: 1.12 % w/w (by KF) The powder XRD and LR spectra obtained were similar to those shown in Figures 1 and 2 respectively.
Example 2 Crystalline repaglinide (lOg) was dissolved in 150 mL of acetone at room temperature. The clear solution thus obtained was subjected to spray drying in a mini spray dryer (Buchi Model 190). The spray drier was configured to utilize a nitrogen gas inlet at 700mm of Hg and flow rate was set at 10.0 mL/minute. The inlet temperature was maintained at 56 °C and accordingly, the outlet temperature was 35 °C. Repaglinide was charged in the spray drier for 15 minutes and 7.0 g of white fluffy powder was collected.
Moisture content: 1.09 % w/w (by KF) The powder XRD and LR spectra obtained were similar to those shown in Figures land 2 respectively.

Claims

We Claim:
1. A process for the preparation of an amoφhous form of repaglinide, which comprises recovering amoφhous repaglinide from a repaglinide solution by spray drying.
2. The process according to claim 1, wherein the repaglinide solution is obtained directly from a reaction mixture.
3. The process according to claim 1, wherein the repaglinide solution is obtained by dissolving crystalline repaglinide in a suitable solvent.
4. The process according to claim 1, wherein the suitable solvent is selected from the group consisting of alcohols, ketones, ethers, chlorinated hydrocarbons, esters, nitriles, dipolar aprotic solvents, cyclic ethers, and mixtures thereof.
5. The process according to claim 4, wherein the suitable solvent is selected from the group consisting of methanol, ethanol, isopropanol, dichloromethane, dichloroethane, acetonitrile, tetrahydrofuran, dioxane, diethylether, diisopropylether, tertiary butylethylether, and mixtures thereof.
6. The process according to claim 4, wherein the spray drier has an air inlet temperature of from about 40 °C to about 100 °C and an outlet temperature of from about 20 °C to about 80 °C.
7. A pharmaceutical composition comprising a therapeutically effective amount of an amoφhous form of repaglinide and at least one pharmaceutical acceptable excipient, carrier, or diluent.
8. The pharmaceutical composition of claim 7, wherein the amoφhous form of repaglinide is characterized by a differential scanning calorimetry curve having a single melting endotherm with a peak temperature of about 52.98 °C and an extrapolated onset temperature of about 47.23 °C.
9. The pharmaceutical composition of claim 7, wherein the amoφhous form of repaglinide is formed by recovering amoφhous repaglinide from a repaglinide solution by spray drying.
10. Repaglinide in an amoφhous form.
11. The compound of claim 10 characterized by a differential scanning calorimetry curve having a single melting endotherm with a peak temperature of about 52.98 °C and an extrapolated onset temperature of about 47.23 °C.
12. A method of treating a disease related to hypoglycemic activity comprising administering a therapeutically effective amount of an amoφhous form of repaglinide to a patient in need thereof.
13. The method of claim 12, wherein the patient is a human.
14. A method of treating diabetes mellitus comprising administering a therapeutically effective amount of an amoφhous form of repaglinide to a patient in need thereof.
15. The method of claim 14, wherein the patient is a human.
EP04769193A 2003-08-28 2004-08-27 Process for the preparation of amorphous form of repaglinide Withdrawn EP1664008A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1049DE2003 2003-08-28
PCT/IB2004/002776 WO2005021524A1 (en) 2003-08-28 2004-08-27 Process for the preparation of amorphous form of repaglinide

Publications (1)

Publication Number Publication Date
EP1664008A1 true EP1664008A1 (en) 2006-06-07

Family

ID=34259934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769193A Withdrawn EP1664008A1 (en) 2003-08-28 2004-08-27 Process for the preparation of amorphous form of repaglinide

Country Status (2)

Country Link
EP (1) EP1664008A1 (en)
WO (1) WO2005021524A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177221A1 (en) 2008-10-20 2010-04-21 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of substantially optically pure Repaglinide and precursors thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0589874T3 (en) * 1991-06-21 2000-04-03 Boehringer Ingelheim Pharma Use of (S) (+) -2-ethoxy-4- [N- [1- (2-piperidinophenyl) -3-methyl-1-butyl] aminocarbonylmethyl] benzoic acid to prepare
US20040102477A1 (en) * 2002-08-23 2004-05-27 Dr. Reddy's Laboratories Limited Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2005021524A1 *

Also Published As

Publication number Publication date
WO2005021524A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
AU2005265769B2 (en) 5-substituted-2-phenylamino-benzamides as MEK inhibitors
US6753333B2 (en) Chiral fluoroquinolone arginine salt forms
EA008665B1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
DE102004003428A1 (en) New long-acting beta-2 agonists, and their use as pharmaceuticals
EP1720546B1 (en) Novel, sustained-action beta-2-agonists and their use as medicaments
EP0004532B1 (en) 1-aryloxy-3-nitratoalkylamino-2-propanols, process for their preparation and pharmaceutical compositions
EP1957451A1 (en) Soft anticholinergic zwitterions
EP0290122B1 (en) Morpholine derivatives and their use
EP1861361A1 (en) Glycopyrronium salts and their therapeutic use
EP0171702A1 (en) Benzoxazinone derivatives, preparation and use
US4607033A (en) Morpholine derivatives, compositions and medicinal use
WO2007058971A2 (en) Soft anticholinergic esters
JPS6136829B2 (en)
US4683245A (en) Laevorotatory antipode of moprolol as an antihypertensive
EP1664008A1 (en) Process for the preparation of amorphous form of repaglinide
MXPA02000033A (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2, 2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists.
JPS5827796B2 (en) Theophyrinylmethyldioxolane derivative and its production method
EP1587792B1 (en) Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
CN1214029C (en) 4-amino-6,7-dimethoxy-2-(5-methylsulfonylamino-1,2,3,4-tetrahydroisoquinolin-2-yl)-5-(2-pyridyl) Quinazoline methanesulfonate and polymorphs
DE3807813A1 (en) NEW BENZOCYCLOHEPEN DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
JP2004521082A (en) Novel crystalline form of factor Xa inhibitor
US4692465A (en) 2-phenylethylamine derivatives
EP1102746B1 (en) Substituted phenylamidines with antithrombotic action
WO2005030698A1 (en) Process for the preparation of voglibose
JPH11505815A (en) (2-morpholinylmethyl) benzamine derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060328

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

17Q First examination report despatched

Effective date: 20061228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070508